Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
5 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, CLINICAL ASPECTS OF CANCER-ASSOCIATED THROMBOSIS(2023); Active cancer accounts for 20% of the total incidence of venous thrombembolism (VTE), a condition called cancer-associated thrombosis (CAT) . Cancer is the leading cause of death in patients with VTE and vice versa. Risk factors for VTE can be classified into three groups: patient-related, cancer-related, and treatment-related. This review contains the most relevant, up to date, randomized controlled studies for carcinoma-associated thrombosis, pathogenesis and risk factors for CAT, risk assessment models, and most importantly, recommendation for thromboprophylaxis of patients with carcinoma, treatment of patients with CAT for both, hospitalized and outpatients, and secondary prevention of VTE, comparing efficacy and safety of low-molecular weight heparin (LMWH) to direct oral anticoagulans (DOAC), balancing between the risk of recurrent VTE and major bleeding. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism(2018) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism(Thieme Medical Publishers, 2017) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PREGNANCY WITH POLYCYTHEMIA VERA - AN OBSTETRIC CHALLENGE(DEPARTMENT OF ANAESTHESIA AND REANIMATION, FACULTY OF MEDICINE, “SS. CYRIL AND METHODIUS” UNIVERSITY, SKOPJE, MACEDONIA, 2022); ; ; ; Polycythemia vera (PV) is a rare chronic myeloproliferative disorder of the haematopoietic stem cell type characterized by increased erythrocyte production. The disease is associated to a high risk of clinical complications - arterial and venous thrombosis, especially in pregnancy, bleeding, possible evolution to myelofibrosis and acute myeloid leukemia. We present the case of a 28-years-old patient, whose diagnosis was made 2 years before pregnancy (positive for mutation JAK2 V617F, bcr-abl negative, MPL, CALR negative). She was regularly monitored at the Hematology Clinic, had therapeutic venipunctures performed and anticoagulant therapy was prescribed. Pregnancy was regularly followed, with proper fetal growth and development, regular screening for fetal abnormalities, under anticoagulant therapy and under the supervision of a hematologist. At 34 weeks gestation, due to bleeding and pain, she was hospitalized in the Peripartal Intensive Care Department suspected of placental abruption. A caesarean section was performed immediately, a premature fetus was delivered in relatively good condition, and during the operation abruption of 1/3 of the placenta was found. The operative and postoperative periods were stable, the patient received replacement therapy and was discharged from the hospital on the 5th postoperative day in good general condition. The newborn was stabilized and discharged in good general condition after 3 weeks of stay at the Neonatal Intensive Care Department. Conclusion: Pregnancy in patients with this disease carries serious risks to the life and health of both mother and fetus, which requires special attention during pregnancy in order to reduce antenatal and postnatal morbidity. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hormonal changes in women with abnormal endometrial bleeding in peri and postmenopause(European Society of Endocrinology, 2022-05); ;